The synthetic biology concept continued to be strong. Blue Biotech had 3 consecutive sales, Channing Biotech surged 15%, and Langkun Environmental, Fuxiang Pharmaceutical, and Jiabiyou had advanced gains.

The synthetic biology concept continued to be strong. Blue Biotech had 3 consecutive sales, Channing Biotech surged 15%, and Langkun Environmental, Fuxiang Pharmaceutical, and Jiabiyou had advanced gains.

Zhitong FinanceApr 30 09:47

Express News | Fuxiang Pharmaceutical: Subsidiary passed GMP compliance inspection

BreakingsApr 29 20:53

Express News | Fuxiang Pharmaceutical: net loss of 200 million yuan in 2023

BreakingsApr 28 17:25

Fuxiang Pharmaceutical (300497.SZ): Net profit of 1.468,500 yuan for the first quarter reversed the year-on-year loss

Gelonghui, April 28 | Fuxiang Pharmaceutical (300497.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 340 million yuan, a year-on-year decrease of 14.45%; net profit attributable to shareholders of listed companies was 1.468,500 yuan, which turned a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 10.21 million yuan; basic earnings per share.

Gelonghui FinanceApr 28 16:34

The innovative drug sector fluctuated higher. Alice rose and stopped at 20CM, Sansheng Guojian rose more than 10%, and Tiger Pharmaceuticals, Changshan Pharmaceutical, Fuxiang Pharmaceutical, and Shenzhou Cell registered higher gains.

The innovative drug sector fluctuated higher. Alice rose and stopped at 20CM, Sansheng Guojian rose more than 10%, and Tiger Pharmaceuticals, Changshan Pharmaceutical, Fuxiang Pharmaceutical, and Shenzhou Cell registered higher gains.

Zhitong FinanceApr 26 10:09

Express News | Fuxiang Pharmaceutical: The subsidiary passed IATF16949 international automotive quality management system certification

BreakingsApr 19 08:31